高级检索

靶向微粒体前列腺素E2合酶-1的抗炎药物研究进展

Research advances in microsomal prostaglandin E2 synthase-1 targeted anti-inflammatory drugs

  • 摘要: 微粒体前列腺素E2合酶-1(mPGES-1)是介导前列腺素E2(PGE2)产生的主要终末合成酶,在炎症性疾病中起着至关重要的作用。与非甾体抗炎药相比,mPGES-1抑制剂在阻断PGE2的产生方面具有更好的特异性和更高的安全性,因此被认为是更具前景的抗炎药物。本文总结了mPGES-1分子在炎症和心血管疾病中的研究现状,系统梳理了mPGES-1抑制剂的研究进展,详细阐述了其在不同炎症性动物模型和炎性疾病中的治疗作用,并探讨了可能存在的挑战,以期为后续抗炎药物的研发提供指引和参考。

     

    Abstract: Microsomal prostaglandin E2 synthase 1 (mPGES-1), the main terminal synthase of prostaglandin E2 (PGE2), plays a crucial role in inflammatory diseases. Compared to non-steroidal anti-inflammatory drugs (NSAIDs), mPGES-1 inhibitors are promising agents for their better specificity and higher safety. This article summarizes the research status of mPGES-1 in inflammation and cardiovascular diseases, systematically reviews the research progress of the development of mPGES-1 inhibitors, elaborates on their therapeutic effects in different inflammation animal models and inflammatory diseases, and discusses the possible existing challenges, aiming to provide some guidance and reference for the subsequent research of anti-inflammatory drugs.

     

/

返回文章
返回